Total Payments
$1.8M
2024 Payments
$151,796
Companies
25
Transactions
1,248
Medicare Patients
863
Medicare Billing
$169,808
Payment Breakdown by Category
Other$1.0M (56.1%)
Consulting$365,557 (20.5%)
Travel$200,996 (11.3%)
Research$194,306 (10.9%)
Food & Beverage$21,963 (1.2%)
Education$22.61 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $929,547 | 275 | 52.1% |
| Consulting Fee | $365,557 | 117 | 20.5% |
| Travel and Lodging | $200,996 | 521 | 11.3% |
| Unspecified | $194,306 | 14 | 10.9% |
| Honoraria | $46,778 | 25 | 2.6% |
| Food and Beverage | $21,963 | 274 | 1.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $21,335 | 19 | 1.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,965 | 1 | 0.2% |
| Education | $22.61 | 2 | 0.0% |
Payments by Type
General
$1.6M
1,234 transactions
Research
$194,306
14 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $548,014 | 414 | $0 (2024) |
| ABBVIE INC. | $270,684 | 65 | $0 (2024) |
| Celgene Corporation | $211,369 | 140 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $208,923 | 146 | $0 (2023) |
| JAZZ PHARMACEUTICALS INC. | $175,771 | 163 | $0 (2024) |
| Daiichi Sankyo Inc. | $96,058 | 80 | $0 (2024) |
| Agios Pharmaceuticals, Inc. | $92,555 | 98 | $0 (2021) |
| SERVIER PHARMACEUTICALS LLC | $76,170 | 77 | $0 (2024) |
| PFIZER INC. | $40,905 | 20 | $0 (2023) |
| Astellas Pharma US Inc | $28,220 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $151,796 | 133 | Incyte Corporation ($60,721) |
| 2023 | $140,206 | 103 | Incyte Corporation ($53,901) |
| 2022 | $112,017 | 93 | Incyte Corporation ($42,084) |
| 2021 | $123,603 | 81 | Incyte Corporation ($40,399) |
| 2020 | $256,406 | 95 | AbbVie Inc. ($105,604) |
| 2019 | $325,569 | 211 | AbbVie, Inc. ($87,496) |
| 2018 | $423,707 | 332 | Incyte Corporation ($110,708) |
| 2017 | $250,165 | 200 | Incyte Corporation ($119,569) |
All Payment Transactions
1,248 individual payment records from CMS Open Payments — Page 1 of 50
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | SERVIER PHARMACEUTICALS LLC | — | Consulting Fee | Cash or cash equivalent | $4,080.00 | General |
| 12/12/2024 | SERVIER PHARMACEUTICALS LLC | — | Consulting Fee | Cash or cash equivalent | $3,400.00 | General |
| 12/10/2024 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,055.00 | General |
| Category: Hematology/Oncology | ||||||
| 12/06/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $130.00 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Consulting Fee | Cash or cash equivalent | $1,128.75 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,370.00 | General |
| Category: Hematology/Oncology | ||||||
| 11/14/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Consulting Fee | Cash or cash equivalent | $2,902.50 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Consulting Fee | Cash or cash equivalent | $3,225.00 | General |
| Category: ONCOLOGY | ||||||
| 11/02/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $79.99 | General |
| Category: ONCOLOGY | ||||||
| 11/02/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: ONCOLOGY | ||||||
| 11/02/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $39.99 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Travel and Lodging | In-kind items and services | $415.80 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Travel and Lodging | In-kind items and services | $268.85 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $39.99 | General |
| Category: ONCOLOGY | ||||||
| 10/16/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | In-kind items and services | $857.69 | General |
| Category: Oncology | ||||||
| 10/16/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | In-kind items and services | $226.94 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,480.00 | General |
| Category: Hematology/Oncology | ||||||
| 10/12/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | In-kind items and services | $476.44 | General |
| Category: Oncology | ||||||
| 10/12/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Travel and Lodging | In-kind items and services | $336.13 | General |
| Category: Oncology | ||||||
| 10/08/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $563.96 | General |
| Category: Hematology/Oncology | ||||||
| 10/08/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $317.62 | General |
| Category: Hematology/Oncology | ||||||
| 10/08/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $116.80 | General |
| Category: Hematology/Oncology | ||||||
| 10/08/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $103.32 | General |
| Category: Hematology/Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| M16-043 | AbbVie Inc. | $96,804 | 2 |
| M16-043 | AbbVie, Inc. | $64,778 | 2 |
| M15-656 | AbbVie, Inc. | $18,869 | 1 |
| Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry (AZA-MDS-006) | Celgene Corporation | $3,342 | 1 |
| AZA-MDS-006 - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry | Celgene Corporation | $3,048 | 1 |
| AZA-MDS-006 | Celgene Corporation | $2,976 | 2 |
| Connect MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry | Celgene Corporation | $1,800 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $749.58 | 2 |
| A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation | Astellas Pharma Global Development | $290.32 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 186 | 609 | $182,410 | $40,484 |
| 2022 | 6 | 253 | 739 | $276,333 | $50,543 |
| 2021 | 6 | 245 | 606 | $226,664 | $44,055 |
| 2020 | 6 | 179 | 553 | $200,583 | $34,726 |
Total Patients
863
Total Services
2,507
Medicare Billing
$169,808
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 93 | 271 | $95,463 | $18,385 | 19.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 39 | 283 | $63,903 | $17,235 | 27.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 20 | $12,216 | $2,400 | 19.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 23 | 24 | $5,658 | $1,485 | 26.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 11 | 11 | $5,170 | $977.58 | 18.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 98 | 264 | $117,744 | $18,561 | 15.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 41 | 346 | $88,230 | $17,673 | 20.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 42 | 52 | $28,472 | $5,435 | 19.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 32 | 32 | $21,952 | $4,406 | 20.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 18 | 20 | $13,560 | $3,082 | 22.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 22 | 25 | $6,375 | $1,385 | 21.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 40 | 296 | $75,480 | $16,503 | 21.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 59 | 136 | $60,656 | $10,240 | 16.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 24 | 25 | $16,950 | $3,881 | 22.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 31 | 33 | $17,886 | $3,789 | 21.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 26 | 26 | $17,836 | $3,617 | 20.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 33 | 54 | $24,084 | $3,252 | 13.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 13 | 16 | $8,672 | $1,682 | 19.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 19 | 20 | $5,100 | $1,090 | 21.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 42 | 288 | $73,440 | $15,834 | 21.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 56 | 176 | $78,496 | $9,616 | 12.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 20 | 23 | $15,594 | $3,475 | 22.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 29 | 34 | $18,428 | $2,927 | 15.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 15 | 15 | $10,290 | $1,992 | 19.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 17 | 17 | $4,335 | $881.49 | 20.3% |
About Dr. Harry Erba, MD
Dr. Harry Erba, MD is a Internal Medicine healthcare provider based in Ann Arbor, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508942566.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Harry Erba, MD has received a total of $1.8M in payments from pharmaceutical and medical device companies, with $151,796 received in 2024. These payments were reported across 1,248 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($929,547).
As a Medicare-enrolled provider, Erba has provided services to 863 Medicare beneficiaries, totaling 2,507 services with total Medicare billing of $169,808. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology, Medical Oncology
- Location Ann Arbor, MI
- Active Since 10/31/2006
- Last Updated 03/01/2012
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1508942566
Products in Payments
- JAKAFI (Drug) $465,496
- VENCLEXTA (Drug) $171,619
- VYXEOS (Drug) $160,354
- Revlimid (Drug) $114,012
- TIBSOVO (Drug) $108,512
- TASIGNA (Drug) $103,824
- Venclexta (Drug) $87,528
- ONUREG (Drug) $61,853
- GLEEVEC (Drug) $48,210
- RYDAPT (Drug) $30,495
- Vanflyta (Drug) $28,194
- Tibsovo (Drug) $27,863
- MYLOTARG (Biological) $21,044
- ONCASPAR (Drug) $19,617
- XOSPATA (Drug) $18,976
- REBLOZYL (Biological) $10,428
- Xospata (Drug) $9,534
- BESPONSA (Biological) $9,028
- CC-486 (Drug) $7,224
- LORBRENA (Drug) $7,001
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Ann Arbor
Dr. Marschall Runge, Md, MD
Internal Medicine — Payments: $2.3M
Internal Medicine $2.3M
Terry Smith, M.d, M.D
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Dr. Dinesh Khanna, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Alexander Yevzlin, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Vallerie Mclaughlin, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M
Meilan Han, Md, MD
Internal Medicine — Payments: $909,137
Internal Medicine $909,137